<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58290">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347189</url>
  </required_header>
  <id_info>
    <org_study_id>10154745DOC</org_study_id>
    <nct_id>NCT02347189</nct_id>
  </id_info>
  <brief_title>Melody(TM) TPV PB1016 Surveillance Study</brief_title>
  <acronym>Melody PB1016</acronym>
  <official_title>Melody(TM) Transcatheter Pulmonary Valve PB1016 Surveillance Study Implantation of the Medtronic Melody Transcatheter Pulmonary Valve PB1016 Using the Ensemble(TM) Transcatheter Delivery System in Patients With Dysfunctional RVOT Conduits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Heart Valves</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, multi-center, prospective surveillance study to investigate and assess the
      residual risks, and to confirm the currently established safety and performance of the
      Melody TPV PB1016.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptable TPV Hemodynamic Function</measure>
    <time_frame>6 Months</time_frame>
    <description>Acceptable TPV hemodynamic function at six months after successful TPV implantation which is determined as a composite of the following:
Mean RVOT gradient ≤ 30 mmHg
Severity of pulmonary regurgitation less than moderate
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at six months post-implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptable Hemodynamic Function</measure>
    <time_frame>1 Year</time_frame>
    <description>Acceptable TPV hemodynamic function at 1 year after successful TPV implantation which is determined as a composite of the following:
Mean RVOT gradient is ≤ 30 mmHg as measured by CW Doppler
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at 1 year post-TPV implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptable Hemodynamic Function</measure>
    <time_frame>2 Years</time_frame>
    <description>Acceptable TPV hemodynamic function at 2 years after successful TPV implantation which is determined as a composite of the following:
Mean RVOT gradient is ≤ 30 mmHg as measured by CW Doppler
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at 2 years post-TPV implantation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of Safety</measure>
    <time_frame>6 Months, 1 Year, 2 Years</time_frame>
    <description>Serious procedure-related adverse events
Serious device-related adverse events at 6 months, 1 year and 2 years post-implant
Freedom from stent fracture at 6 months, 1 year and 2 years post-implant
Freedom from catheter re-intervention on the Melody TPV PB1016 at 6 months, 1 year and 2 years post-implant
Freedom from RVOT conduit reoperation at 6 months, 1 year and 2 years post-implant
Freedom from death (all-cause, procedural, and device-related) at 6 months, 1 year and 2 years post-implant</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Procedural Success</measure>
    <time_frame>At Time Of Procedure</time_frame>
    <description>A successful implant is defined as follows:
Melody TPV PB1016 is fixated within the desired location
RV-PA peak-to-peak gradient measured in the catheterization lab after Melody TPV PB1016 implantation is &lt; 35 mmHg
No more than trace/trivial pulmonary regurgitation by angiography
Subject is free from explantation of the Melody TPV PB1016 at 24 hours post-implant.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects</condition>
  <arm_group>
    <arm_group_label>Melody TPV PB1016</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Melody Transcatheter Pulmonary Valve PB1016</intervention_name>
    <arm_group_label>Melody TPV PB1016</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient eligible to receive Melody TPV PB1016 per current Instructions for Use (IFU)
             indications at time of study enrollment

          -  Patient (or patient's legally authorized representative) is willing to consent to
             participate in the study and will commit to completion of all follow-up requirements.

        Exclusion Criteria:

          -  Implantation in the aortic, tricuspid, or mitral position

          -  Venous anatomy unable to accommodate a 22-Fr size introducer sheath

          -  Obstruction of the central veins

          -  Clinical or biological signs of infection including active endocarditis

          -  History of intravenous substance abuse

          -  Currently participating in an investigational drug or device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Childrens Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens and Regional Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landes-Kinderklinik</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stollery Childrens Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>September 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
